Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1.

For primary outcomes, when compared with PR, all interventions, including SMV plus PR (OR 3.55, 95% CI 2.22–5.69, P < 0.001), FDV plus PR (OR 3.61, 95% CI 1.74–7.51, P < 0.001), SOF plus PR (OR 4.41, 95% CI 1.61–12.04, P < 0.001), BEC plus PR (OR 14.64, 95% CI 10.58, 18.70, P < 0.001), DCV plus PR (OR 7.80, 95% CI 1.75–34.83, P < 0.001) and TLV plus PR (OR 3.42, 95% CI 2.03–5.75, P < 0.001), showed significant clinical efficacy for SVR12, except for LDV plus SOF plus PR, which showed a trend that it was associated with decreasing SVR12 (Table 3 ).

also in 53,322 other papers